^
Association details:
Biomarker:No biomarker
Cancer:Mantle Cell Lymphoma
Regimen:R-CHOP (cyclophosphamide + doxorubicin hydrochloride + + Rituxan (rituximab) + vincristine)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
Source:
Published date:
01/20/2021
Excerpt:
Mantle Cell Lymphoma: INDUCTION THERAPY…Preferred Regimens…Alternating RCHOP/RDHAP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone)/(rituximab, dexamethasone, cytarabine, cisplatin)